EHMT1 anticorps

N° du produit ABIN966204

Cité dans 2 publications. Cet anticorps anti-EHMT1 Monoclonal (ABIN966204) détecte spécifiquement EHMT1 dans WB et ELISA. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour EHMT1 anticorps (ABIN966204)

Antigène: EHMT1 (Euchromatic Histone-Lysine N-Methyltransferase 1 (EHMT1))

Reactivité: Humain

Hôte: Veuillez nous consulter SVP

Clonalité: Monoclonal

Conjugué: Cet anticorp EHMT1 est non-conjugé

Application: Western Blotting (WB), ELISA

Détail du produit anti-EHMT1 anticorps

Specificité: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)

Purification: Antibodies are purified by protein A affinity chromatography

Isotype: IgG1

Information d'application

Indications d'application: Western Blot: Dilution 1: 200- 1: 1,000
ELISA: Propose dilution 1: 10,000
Determining optimal working dilutions by titration test.

Restrictions: For Research Use only

Stockage

Stock: -20 °C

Références pour anticorps anti-EHMT1 (ABIN966204)

Young: "Inhibition of glucagon secretion." dans: Advances in pharmacology (San Diego, Calif.), Vol. 52, pp. 151-71, (2006) (PubMed).

De León, Crutchlow, Ham, Stoffers: "Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus." dans: The international journal of biochemistry & cell biology, Vol. 38, Issue 5-6, pp. 845-59, (2006) (PubMed).

Détails sur EHMT1

Antigène: EHMT1 (Euchromatic Histone-Lysine N-Methyltransferase 1 (EHMT1))

Autre désignation: GLP

Sujet: Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L cells in response to ingested nutrients. The closely related peptides glucagon-like peptide (GLP-1) and glucagon have opposing effects on blood glucose. GLP-1 induces glucose-dependent insulin secretion in the pancreas, while glucagon stimulates gluconeogenesis and glycogenolysis in the liver. Glucagon is processed from a large precursor, proglucagon, in a tissue-specific manner in pancreatic alpha-cells. The identification of a hybrid peptide acting as both a GLP-1 agonist and a glucagon antagonist would provide a novel approach for the treatment of type 2 diabetes.

ID gène: 79813